Business Wire

CT-XEROX

7.7.2020 14:02:04 CEST | Business Wire | Press release

Share
Xerox Adaptive CMYK+ Kit for Xerox Versant Expands Color Palette to More Than a Million

Xerox announced the Xerox Adaptive CMYK+ Kit for Xerox Versant® , the print market’s first adaptive technology kit that adds seven specialty colors to an existing production press, enabling instant digital print enhancements. The kit transforms a four-color Xerox Versant® 180 Press into an 11-color Beyond CMYK press capable of creating a million color hues and shades by adding gold, silver, white, clear and fluorescent colors of yellow, magenta and cyan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005242/en/

Digital enhancement of print is projected to be a $25 billion market¹, but access to that opportunity usually requires a capital investment in a new press with the ability to print Beyond CMYK. The Xerox Adaptive CMYK+ Kit for Versant gives print providers the ability to simply swap out toners to print colors and enhancements that increase profitability and deliver higher margins without needing a new press.

“The Versant CMYK+ Adaptive Kit delivers what print providers need – the ability to provide higher value offerings without major investment,” says Marybeth Gilbert, vice president and general manager, Production Business, Xerox. “The Versant kit further expands Xerox’s market leading Beyond CMYK portfolio, providing our customers opportunity for digital print enhancements from large volume print shop, to light production and into the office space.”

According to Keypoint Intelligence, print providers can increase profit margins on digital enhancements between 50 and 400 percent versus ordinary print. Also, promotional printing such as marketing collateral, brochures, business cards, and signage is the most common application category for embellishments². The Versant 180 is uniquely suited and designed for such uses so print providers can easily convert, enhance and charge more for ordinary jobs.

The Xerox Adaptive CMYK+ Kit for Xerox Versant has three options: the Xerox Vivid Kit (gold, silver, white and clear), Xerox Fluorescent Kit (cyan, magenta and yellow) – or the combination Xerox Vivid + Fluorescent Kit for all 11 colors. The adaptive kit works with EFI DFE versions of the Versant 180 and Versant 180 with Performance Package.

Availability:
The Xerox Adaptive CMYK+ Kit for Xerox Versant is available now for order taking in both EMEA and the Americas. The kit will be available for delivery in EMEA on July 15, 2020 and in the Americas on August 17, 2020.

About Xerox
Xerox Holdings Corporation makes every day work better.
We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .

¹ Keypoint Intelligence/Infotrends, “Beyond CMYK: The Use of Special Effects in Digital Printing”
² Keypoint Intelligence/Infotrends, “Market Opportunities for CMYK+”

Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .

Xerox® is a trademark of Xerox in the United States and/or other countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/XeroxCorp/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye